Physicians' Academy for Cardiovascular Education
Member
Managing CKD, Diabetes & CVD:  Is epigenetics a new way forward?

Managing CKD, Diabetes & CVD: Is epigenetics a new way forward?

June 5, 2017 - CME symposium at ERA-EDTA 2017, Madrid, Spain

Introduction

The aim of this educational programme is to provide a balanced overview on a novel approach to reduce residual CV risk in patients with increase cardiovascular and renal risk, namely BET inhibition. BET refers to a bromodomain and extra-terminal domain of regulatory proteins. Its inhibition modifies gene expression via epigenetic mechanisms.

Date and venue

Educational objectives

Agenda

Co-chairman

Topics

CME accreditation

CME accredition is applied for by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit

Funding

The symposium is supported by an unrestricted educational grant from Resverlogix Corp